Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, Double-blind, Placebo-controlled Crossover Study of SAGE-718 Using a Ketamine Challenge, to Evaluate the Electrophysiology, Safety, Tolerability, and Pharmacokinetics in Healthy Subjects

Next Previous
Trial Profile

A Phase 1, Double-blind, Placebo-controlled Crossover Study of SAGE-718 Using a Ketamine Challenge, to Evaluate the Electrophysiology, Safety, Tolerability, and Pharmacokinetics in Healthy Subjects

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 17 Dec 2019

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dalzanemdor (Primary) ; Ketamine
  • Indications Encephalitis; Smith-Lemli-Opitz syndrome
  • Focus Pharmacodynamics
  • Sponsors Sage Therapeutics

Most Recent Events

  • 10 Dec 2019 According to a Sage Therapeutics media release, data were presented at the 2019 Annual Meeting of the American College of Neuropsychopharmacology (ACNP).
  • 10 Dec 2019 Results presented in a Sage Therapeutics Media Release.
  • 08 Feb 2019 Status changed from recruiting to completed.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top